OP0133 Cardiovascular safety profile of rofecoxib: a meta-analysis

Abstract

Conclusion This independent-confirmatory study demonstrated that glucosamine sulfate can be postulated as the first osteoarthritis structure modifying agent. Glucosamine sulfate also improved the disease symptoms in the long-term treatment of the disease, with a safety profile similar to placebo. The action of glucosamine sulfate on both the structure and the symptoms evolution of the disease postulate it as the first osteoarthritis modifying agent. REFERENCE